NASDAQ:PRAN - Prana Biotechnology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.40 +0.07 (+5.26 %) (As of 12/14/2018 04:00 PM ET)Previous Close$1.40Today's Range$1.30 - $1.515252-Week Range$1.30 - $3.79Volume9,106 shsAverage Volume23,713 shsMarket Capitalization$11.83 millionP/E Ratio-2.00Dividend YieldN/ABeta0.01 ProfileDiscussionAnalyst RatingsChartFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia. Receive PRAN News and Ratings via Email Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRAN Previous Symbol CUSIPN/A Webwww.pranabio.com Phone61-3-9349-4906 Debt Debt-to-Equity RatioN/A Current Ratio7.09 Quick Ratio7.09 Price-To-Earnings Trailing P/E Ratio-2.00 Forward P/E Ratio-1.79 P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales83.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book1.00 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees14 Outstanding Shares8,900,000Market Cap$11.83 million OptionableNot Optionable Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions What is Prana Biotechnology's stock symbol? Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN." What price target have analysts set for PRAN? 1 brokerages have issued 12-month price objectives for Prana Biotechnology's shares. Their forecasts range from $4.00 to $4.00. On average, they expect Prana Biotechnology's stock price to reach $4.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View Analyst Price Targets for Prana Biotechnology. What is the consensus analysts' recommendation for Prana Biotechnology? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prana Biotechnology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Prana Biotechnology. Has Prana Biotechnology been receiving favorable news coverage? News coverage about PRAN stock has trended somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Prana Biotechnology earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Prana Biotechnology's key competitors? Some companies that are related to Prana Biotechnology include Conatus Pharmaceuticals (CNAT), Forward Pharma A/S (FWP), Aptevo Therapeutics (APVO), Nemus Bioscience (NMUS), Evoke Pharma (EVOK), Catabasis Pharmaceuticals (CATB), DiaMedica Therapeutics (DMCAF), Zosano Pharma (ZSAN), Leap Therapeutics (LPTX), Vascular Biogenics (VBLT), Clearside Biomedical (CLSD), GT Biopharma (GTBP), ProPhase Labs (PRPH), Helix Biopharma (HBPCF) and Novan (NOVN). Who are Prana Biotechnology's key executives? Prana Biotechnology's management team includes the folowing people: Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 63)Ms. Kathryn Andrews B.Com, CPA, Chief Financial Officer (Age 51)Dr. David A. Stamler M.D., Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 57)Prof. Rudolph Emile Tanzi Ph.D., Chief Scientific Advisor and Member of R&D Advisory BoardDr. Steven D. Targum M.D., Chief Medical Advisor How do I buy shares of Prana Biotechnology? Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Prana Biotechnology's stock price today? One share of PRAN stock can currently be purchased for approximately $1.40. How big of a company is Prana Biotechnology? Prana Biotechnology has a market capitalization of $11.83 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-6,400,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Prana Biotechnology employs 14 workers across the globe. What is Prana Biotechnology's official website? The official website for Prana Biotechnology is http://www.pranabio.com. How can I contact Prana Biotechnology? Prana Biotechnology's mailing address is Level 3 460 Bourke Street, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected] MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 124 (Vote Outperform)Underperform Votes: 152 (Vote Underperform)Total Votes: 276MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: What is systematic risk?